ImpediMed (IPD) Q4 2024 TU earnings summary

Executive summary

• Q4 saw strong momentum with 38 SOZO units sold (23 in the US), a 168% increase in the sales lead pipeline, and expansion into three major US networks, driven by enhanced marketing and sales efforts.

• Leadership and board changes, including the appointment of Fiona Bones and other key executives, have set a new strategic direction focused on growth and operational efficiency.

• The SOZO platform remains the only FDA-cleared technology for BCRL detection, reinforcing market leadership and clinical adoption.

• Real-world evidence and economic studies, such as the NSW Health Lymphoedema Prevention Program, demonstrate strong ROI and cost-effectiveness for SOZO adoption.

• Financials, including revenues and costs, are trending positively, with a focus on break-even and new market expansion.

Financial highlights

• Q4 FY24 revenue was A$2.9 million, up from A$2.6 million in Q3 FY24, representing a 10% year-over-year increase.

• 38 SOZO units sold in Q4 FY24 (23 in the US), compared to 18 units in Q3.

• Total contracted value for Q4 was A$3.4 million, up from A$2.2 million in Q3.

• Annual Recurring Revenue (ARR) at June 30, 2024, is A$11.0 million, up from A$10.1 million at March 31, 2024.

• Net operating cash outflows were A$4.7 million, with a cash balance of A$24.6 million at quarter-end.

Outlook and guidance

• Targeting break-even on a free cash flow basis within two years (FY2026), with FY25 operating cash expenditure expected to be 10% lower than FY24.

• Strategic priorities include accelerating US sales, expanding reimbursement coverage, and developing new markets.

• Continued investment in product development, with a new roadmap to be completed by end of Q1 FY25.